UP421: first-in-human hypoimmune islet transplant without immunosuppression: review notes

Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.

Registry: NCT06239636; RECRUITING; updated 2024-12-11; enrollment 2 (ESTIMATED); results not posted.

Endpoint comparison: Safety as assessed by number of treatment related adverse events accoridng to CTCAE v 5.0 (12 months).

Sources for this record: First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes (registry); Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression (peer-reviewed); Long-term follow-up of hypoimmune islet transplantation (peer-reviewed); Sana: publication of 14-month UP421 follow-up (manufacturer).

Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.

Outcome and correction: Corrected estimated enrollment two versus one published recipient. Removed ranking superlatives and unsupported 2–7%/15–50-fold dose extrapolation. Added primary 2025 report, 2026 follow-up citation, and exact sponsor update. Added restrictive eligibility.

Primary sources checked: NEJM 2025; NEJM 2026 letter metadata; Sana July 13, 2026 follow-up; Registry NCT06239636.

Limits: 2025 abstract reviewed; 2026 letter metadata verified but full letter not independently retrieved. Follow-up details attributed to Sana. One low-dose recipient cannot establish insulin independence or uncommon harms.